BRPI0413439A - combinações compreendendo estaurosporinas - Google Patents
combinações compreendendo estaurosporinasInfo
- Publication number
- BRPI0413439A BRPI0413439A BRPI0413439-7A BRPI0413439A BRPI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- ihda
- flt
- malignancies
- combinations
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 abstract 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 2
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 abstract 2
- 230000036210 malignancy Effects 0.000 abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 2
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49382803P | 2003-08-08 | 2003-08-08 | |
| PCT/EP2004/008848 WO2005014004A1 (en) | 2003-08-08 | 2004-08-06 | Combinations comprising staurosporines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413439A true BRPI0413439A (pt) | 2006-10-17 |
Family
ID=34135288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413439-7A BRPI0413439A (pt) | 2003-08-08 | 2004-08-06 | combinações compreendendo estaurosporinas |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070191338A1 (enExample) |
| EP (2) | EP2305265A1 (enExample) |
| JP (1) | JP2007501774A (enExample) |
| CN (1) | CN100536850C (enExample) |
| AU (1) | AU2004262927B2 (enExample) |
| BR (1) | BRPI0413439A (enExample) |
| CA (1) | CA2533861A1 (enExample) |
| MX (1) | MXPA06001524A (enExample) |
| WO (1) | WO2005014004A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| GB0419159D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| WO2006066133A2 (en) | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP2008540574A (ja) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2617898A1 (en) * | 2005-08-09 | 2007-02-15 | Martin Schuler | Staurosporine derivatives for treating non-small cell lung cancer |
| WO2007030455A2 (en) * | 2005-09-07 | 2007-03-15 | Novartis Ag | Mutations and polymorphisms of hdac10 |
| GB0522932D0 (en) * | 2005-11-10 | 2005-12-21 | Univ Southampton | PKC412 in treatment of atypical chronic myeloid leukemia |
| GB0612542D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Combinations comprising staurosporines |
| EA019033B1 (ru) | 2008-03-26 | 2013-12-30 | Новартис Аг | Ингибиторы дезацетилазы в, основанные на гидроксамате |
| US20110053925A1 (en) * | 2009-08-28 | 2011-03-03 | Novartis Ag | Hydroxamate-Based Inhibitors of Deacetylases |
| CN102101866A (zh) * | 2010-11-04 | 2011-06-22 | 中国海洋大学 | 十字孢碱卤代衍生物及其制备方法和应用 |
| CA2878873C (en) * | 2012-07-13 | 2018-08-21 | Turun Yliopisto | A pharmaceutical combination including a histone deacetylase 4 (hdac4) silencing agent for treating cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62220196A (ja) | 1986-03-20 | 1987-09-28 | Kyowa Hakko Kogyo Co Ltd | 新規物質ｕｃｎ―０１ |
| IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| GB8803048D0 (en) | 1988-02-10 | 1988-03-09 | Hoffmann La Roche | Substituted pyrroles |
| IL89167A (en) | 1988-02-10 | 1994-02-27 | Hoffmann La Roche | Substituted pyrroles, their manufacture and pharmaceutical compositions containing them |
| MC2096A1 (fr) | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
| CA2046801C (en) | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
| EP0540185A1 (en) | 1991-10-10 | 1993-05-05 | Schering Corporation | 4'-(N-substituted-N-oxide)staurosporine derivatives |
| US5344926A (en) | 1992-06-22 | 1994-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing staurosporine derivatives |
| US5461146A (en) | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
| PH30300A (en) | 1993-05-07 | 1997-01-20 | Ciba Geigy Ag | Polycyclic compounds and processes for the preparation thereof |
| AU678435B2 (en) | 1993-05-10 | 1997-05-29 | F. Hoffmann-La Roche Ag | Substituted pyrroles |
| CN1050844C (zh) | 1993-12-07 | 2000-03-29 | 伊莱利利公司 | 蛋白激酶ｃ抑制剂 |
| GB9325395D0 (en) | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
| EP0763040A1 (en) | 1994-06-01 | 1997-03-19 | Novartis AG | Carbazole derivatives as agents against multi-drug resistance |
| WO1995032976A1 (en) | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents |
| EP0711556A1 (de) | 1994-11-09 | 1996-05-15 | Ciba-Geigy Ag | Intravenöse Lösungen für ein Staurosporinderivat |
| EP0733372A3 (de) | 1995-03-21 | 1998-05-20 | Ciba-Geigy Ag | Pharmazeutische Formulierungsgrundlage für Nanosuspensionen |
| NL1003692C2 (nl) | 1996-07-26 | 1998-01-28 | Stork Protecon Langen Bv | Inrichting voor het afscheiden van vleesmassa van van vleesresten voorziene botten. |
| CO4940430A1 (es) | 1997-07-07 | 2000-07-24 | Novartis Ag | Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales |
| DE19744676A1 (de) * | 1997-10-10 | 1999-04-15 | Forschungszentrum Borstel Zent | Kombinationspräparate für die Therapie von Tumoren |
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| AR035885A1 (es) * | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| TWI302836B (en) * | 2001-10-30 | 2008-11-11 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| CN102304110A (zh) * | 2003-04-07 | 2012-01-04 | Axys药物公司 | 作为治疗剂的异羟肟酸酯 |
| EP1628651A2 (en) * | 2003-05-21 | 2006-03-01 | Novartis AG | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
-
2004
- 2004-08-06 CA CA002533861A patent/CA2533861A1/en not_active Abandoned
- 2004-08-06 BR BRPI0413439-7A patent/BRPI0413439A/pt not_active IP Right Cessation
- 2004-08-06 US US10/567,897 patent/US20070191338A1/en not_active Abandoned
- 2004-08-06 EP EP10175357A patent/EP2305265A1/en not_active Withdrawn
- 2004-08-06 JP JP2006522329A patent/JP2007501774A/ja active Pending
- 2004-08-06 AU AU2004262927A patent/AU2004262927B2/en not_active Ceased
- 2004-08-06 CN CNB2004800227221A patent/CN100536850C/zh not_active Expired - Fee Related
- 2004-08-06 EP EP04763879A patent/EP1653973A1/en not_active Withdrawn
- 2004-08-06 WO PCT/EP2004/008848 patent/WO2005014004A1/en not_active Ceased
- 2004-08-06 MX MXPA06001524A patent/MXPA06001524A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004262927A1 (en) | 2005-02-17 |
| US20070191338A1 (en) | 2007-08-16 |
| CN1832747A (zh) | 2006-09-13 |
| AU2004262927B2 (en) | 2008-05-22 |
| EP2305265A1 (en) | 2011-04-06 |
| CN100536850C (zh) | 2009-09-09 |
| EP1653973A1 (en) | 2006-05-10 |
| JP2007501774A (ja) | 2007-02-01 |
| WO2005014004A1 (en) | 2005-02-17 |
| MXPA06001524A (es) | 2006-05-15 |
| CA2533861A1 (en) | 2005-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260127B (en) | mek inhibitors and methods of using them | |
| BRPI0413439A (pt) | combinações compreendendo estaurosporinas | |
| BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| CA2414967A1 (en) | Valproic acid and derivatives thereof as histone deacetylase inhibitors | |
| DK1343492T3 (da) | Behandling af mucositis | |
| BRPI0414908A (pt) | compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal | |
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| ATE408601T1 (de) | Fredericamycin-derivate | |
| MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
| CY1109229T1 (el) | Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο | |
| BRPI0507198A (pt) | derivados de bisariluréia | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| EA200500782A1 (ru) | Лечение геморрагического шока | |
| PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
| WO2007147613A3 (en) | Combinations comprising staurosprorines | |
| TW200510367A (en) | Novel lapachone compounds, their preparation, and the use thereof | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| EA202190753A1 (ru) | Состав, содержащий озонированное масло, для лечения опухоли | |
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
| NO20076657L (no) | Kombinasjonsterapi av cancer med AZD2171 og gemcitabin | |
| NO20021437D0 (no) | Fremgangsmate til forebyggelse av kolorektal kreft | |
| NO20064753L (no) | Kombinasjonsterapi | |
| NO20051261L (no) | Morfin-6-glukuronidsalt | |
| BR0314821A (pt) | Derivado de piperidina, composição farmacêutica, uso do derivado de piperidina, e, método para tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição de um corpo animal vivo | |
| NO20054723L (no) | Behandling av proliferative sykdommer med epofilonderivater og straling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2266 DE 10/06/2014. |